Es would most likely not have been affected. The measures of immune activation were not assessed at enrollment into the study cohort, and we therefore cannot make temporal inferences of a causal nature nor could we control for them in the multivariable Cox models. We used prevalence rate ratios (PRRs) to estimate the associations of interest as risk was our parameter of interest. We chose PRRs as
Es would most likely not have been affected. The measures of immune activation were not assessed at enrollment into the study cohort, and we therefore cannot make temporal inferences of a causal nature nor could we control for them in the multivariable Cox models. We used prevalence rate ratios (PRRs) to estimate the associations of interest as risk was our parameter of interest. We chose PRRs as
Es would most likely not have been affected. The measures of immune activation were not assessed at enrollment into the study cohort, and we therefore cannot make temporal inferences of a causal nature nor could we control for them in the multivariable Cox models. We used prevalence rate ratios (PRRs) to estimate the associations of interest as risk was our parameter of interest. We chose PRRs as
Ow-up will be needed to determine whether HCV cure through the use of direct-acting antivirals among HIV/ HCV coinfected elite controllers will make the risk for complications among these patients similar to their HIV monoinfected counterparts. Further studies will also be needed to determine the effects of antiretroviral therapy in this group of patients coupled to its risk/benefit ratio. Whereas
Ing administration of rifabutin 300 mg once daily (Treatment A, #) or rifabutin 300 mg once daily plus SQV-SGC 1200 mg three times daily (Treatment C, ).treatment was greater (33 ) compared to when coadministered with saquinavir (21 ). The within patient variability was approximately 29 .Effects of rifabutin on saquinavirpharmacokineticsThe mean ( CV) AUC(0,8 h), Cmax and C8 for saquinavir when a
Ing administration of rifabutin 300 mg once daily (Treatment A, #) or rifabutin 300 mg once daily plus SQV-SGC 1200 mg three times daily (Treatment C, ).treatment was greater (33 ) compared to when coadministered with saquinavir (21 ). The within patient variability was approximately 29 .Effects of rifabutin on saquinavirpharmacokineticsThe mean ( CV) AUC(0,8 h), Cmax and C8 for saquinavir when a
Ing administration of rifabutin 300 mg once daily (Treatment A, #) or rifabutin 300 mg once daily plus SQV-SGC 1200 mg three times daily (Treatment C, ).treatment was greater (33 ) compared to when coadministered with saquinavir (21 ). The within patient variability was approximately 29 .Effects of rifabutin on saquinavirpharmacokineticsThe mean ( CV) AUC(0,8 h), Cmax and C8 for saquinavir when a
Lications, even after controlling for CD4+ Tcell level, sex, and older age. Chronic inflammation is thought to be associated with CD4+ T-cell depletion and higher levels of immune activation.[21,26] Similarly, HCV coinfection remained significantly associated with a higher prevalence of complications when individual immune activation markers were controlled for. This study found that HCV coinfecte